Evidence network for deaths_(OS)

1IMpassion-130 (all population), 20181IMpassion-131 (all population), 20201KEYNOTE-355 (all population), 20201PAKT (all population), 20201LOTUS, 20171BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 20181TORCHLIGHT, 2024nab-paclitaxelpaclitaxelStandard of Care (SoC)nab-paclitaxel plus placeboatezolizumab plus nab-paclitaxelatezolizumab plus paclitaxelpembrolizumab plus SoCcapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatinnab-paclitaxel plus toripalimabdirect evidencenetwork meta-analysis
T vs. C nab-paclitaxelpaclitaxelStandard of Care (SoC)nab-paclitaxel plus placeboatezolizumab plus nab-paclitaxelatezolizumab plus paclitaxelpembrolizumab plus SoCcapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatinnab-paclitaxel plus toripalimab
nab-paclitaxel---NANANANANANANANANANA
paclitaxelNA---NANANANANANANANANA
Standard of Care (SoC)NANA---NANANANANANANANA
nab-paclitaxel plus placeboNANANA---NANANANANANANA
atezolizumab plus nab-paclitaxelNANANANA---NANANANANANA
atezolizumab plus paclitaxelNANANANANA---NANANANANA
pembrolizumab plus SoCNANANANANANA---NANANANA
capivasertib plus paclitaxelNANANANANANANA---NANANA
ipatasertib plus paclitaxelNANANANANANANANA---NANA
veliparib plus paclitaxel plus carboplatinNANANANANANANANANA---NA
nab-paclitaxel plus toripalimabNANANANANANANANANANA---

pathologies: 60 - treatments: 1575 result logic